Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
周二，AngioDynamics公司（纳斯达克：ANGO）报告称，2024年第四季度的调整后每股收益亏损5美分，与共识亏损16美分相比。
Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from Benzinga Pro.
第四季度销售额为7098万美元，超过分析师共识的7089万美元，根据Benzinga Pro的数据。
Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year.
按比例计算的净销售额增长1.9%，达到7110万美元。医疗技术业务部门的净销售额为2930万美元，同比增长11.3%。
Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales of $5.4 million, representing an increase of 18.0% compared to the fourth quarter of fiscal 2023, and AlphaVac sales of $1.9 million, an increase of 6.8% over the prior year.
创业板来自Auryon 1300万美元的销售增长12.0％，NanoKnife一次性销售额为540万美元，比2023财年第四季度增长18.0％，AlphaVac销售额为190万美元，比去年同期增长6.8％，这些是增长的驱动因素。
Med Device net sales were $41.8 million, a decrease of 3.8% compared to $43.4 million in the prior-year period.
Med Device净销售额为4180万美元，比上年同期下降3.8％，相比去年4340万美元。
AngioDynamics also announced a stock repurchase program of up to $15.0 million.
AngioDynamics还宣布推出最高1500万美元的股票回购计划。
Also Read: AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement.
还阅读：AngioDynamics与Becton，Dickinson达成和解协议，解决了长达十年的专利诉讼。
"We view 2025 as an inflection point in the trajectory of our business...The increased scale of our Med Tech business, in combination with the optimization of our Med Device business, will allow us to begin to see increasing leverage as we exit the year. Operationally, we will continue to work through the transition of our manufacturing model to reduce overhead costs and improve margins in 2026 and beyond," commented Jim Clemmer, President and CEO.
“我们认为2025年是我们业务轨迹的一个转折点......我们医疗技术业务的规模增加，加上我们医疗器械业务的优化，将使我们能够开始在完成这一年之际看到越来越多的杠杆效应。在运营方面，我们将继续通过转型我们的制造模式来减少运营成本并在2026年及以后改善利润率，”Jim Clemmer总裁兼首席执行官发表了上述评论。
Guidance: AngioDynamics expects its fiscal year 2025 net sales of $282 million-$288 million, up 4.2%–6.4% year over year from 2024 pro forma revenue of $270.7 million and compared to the consensus of $287.68 million.
指引：AngioDynamics预计其2025财年净销售额为28200万-28800万美元，比2024年按比例计算的收入27070万美元同比增长4.2%-6.4%，而共识则为28768万美元。
The outlook includes Med Tech net sales to increase 10%-12%, and Med Device net sales are expected to grow 1%-3%.
展望包括医疗技术净销售增长10%-12%，医疗器械净销售预计增长1%-3%。
Gross margin is expected to be approximately 52% to 53% for fiscal year 2025. Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million a year ago.
预计2025财年的毛利率约为52％至53％。与去年同期的按比例计算的320万美元调整后EBITDA亏损相比，预计EBITDA亏损为250万美元至0。
AngioDynamics forecasts fiscal year 2025 adjusted EPS loss of $0.38-$0.42, compared to fiscal 2024 pro forma adjusted EPS loss of $0.45 and consensus loss of $0.49.
AngioDynamics预测2025财年调整后每股收益亏损0.38-0.42美元，而2024财年按比例计算的调整后每股收益亏损为0.45美元，共识亏损为0.49美元。
Price Action: ANGO shares are up 25.6% at $7.445 at last check Tuesday.
股票表现：ANG0股票周二最后交易价为7.445美元，上涨了25.6%。
- Morgan Stanley Q2 Earnings: Higher Profits As Investment Banking Activity Rebounds, On Track To Reach $10T Client Assets.
- 大摩资源lof的Q2收益：随着投资银行业务的复苏，利润增长，有望达到10万亿客户资产。